Community-based molecular and serological surveillance of subclinical malaria in Myanmar

Table 2 Association between qPCR-detectable P. falciparum or P. vivax infection and antibody response

	Contemporaneous infection			Infection at next presentation
	aOR^a	(95%CI)	p value	aOR^b	(95%CI)	p value
PfAMA1 IgG
Seropositive	0.70	(0.52, 0.93)	0.01	0.98	(0.53, 1.80)	0.95
Level (log₂OD 450nm)	0.94	(0.84, 1.06)	0.34	0.91	(0.73, 1.10)	0.33
PfMSP2 IgG
Seropositive	0.81	(0.61, 1.08)	0.15	1.27	(0.70, 2.29)	0.43
Level (log₂OD 450nm)	0.88	(0.80, 0.96)	0.005	0.92	(0.77, 1.11)	0.40
PfCSP IgG
Seropositive	0.51	(0.35, 0.76)	0.001	0.29	(0.07, 1.21)	0.09
Level (log₂OD 450nm)	0.90	(0.83, 0.98)	0.02	1.02	(0.85, 1.24)	0.81
PvAMA1 IgG^c
Seropositive	1.02	(0.73, 1.43)	0.89	–
Level (log₂OD 450nm)	0.98	(0.86, 1.12)	0.75	–

Adjusted for ^aage (years), sex, region, residential status, time (discrete month) and repellent distribution or ^bage (years), sex, region, residential status, time since the last measurement (days) and repellent distribution; ^conly contemporaneous IgG level/seropositivity exposures were estimated for P. vivax infections due to a small number of events for individuals with measurements performed on at least two occasions. Estimates for antigen- specific IgG seropositivity or level are derived from separate equations, (Additional File 2 Tables S3-S10)
aOR adjusted odds ratio, 95%CI 95% confidence interval

ISSN: 1741-7015